Table 2:
ART regimen | N (%) |
---|---|
NNRTI-based regimens | 38 |
Efavirenz-based regimen | 30 (79) |
Nevirapine-based regimen | 8 (21) |
Protease inhibitor-based regimen | 2 |
Atazanavir | 1(2) |
Lopinavir/ritonavir | 1(2) |
ART regimen | N (%) |
---|---|
NNRTI-based regimens | 38 |
Efavirenz-based regimen | 30 (79) |
Nevirapine-based regimen | 8 (21) |
Protease inhibitor-based regimen | 2 |
Atazanavir | 1(2) |
Lopinavir/ritonavir | 1(2) |